Recently, Starczynski et al. 1 described an association of genotypes of the G(-248)A polymorphism located in the promoter region of the bax gene with low Bax expression, more advanced stage, treatment resistance and short overall survival in B-cell chronic lymphocytic leukemia (CLL). Given the key role of apoptosis for the progression of B-CLL, multiple studies have investigated and confirmed the potential role of the Bcl-2 family proteins. 2, 3 In this context, a functional single nucleotide polymorphism in the bax gene, which alters protein function and/or expression, could influence the delicate balance of mechanisms, which regulate apoptosis and thereby impact upon the natural course of CLL. However, related findings from genetic association studies require conformation in independent samples before being universally acceptable.
Currently, Skogsberg et al. 4 could not show any difference in overall survival between patients displaying the G(À248)A polymorphism (median survival 85 months (AA/AG) and 102 months (GG), P ¼ 0.21), and the polymorphism did not influence outcome specifically in treated CLL.
Here, we report a single centre retrospective study of 112 CLL patients designed to evaluate the potential of the G(À248)A bax polymorphism as a prognostic factor. To this end, we also correlated our results with known risk factors, such as disease stage, age, cytogenetics, expression of the CD38 surface antigen and ZAP-70 expression by the leukemic cell clone, and clinical outcome.
Whole peripheral blood samples were usually obtained during routine follow-up visits to our institutions with all patients giving informed consent according to institutional guidelines. Indications for treatment were based on standard criteria.
Genotyping of the G(À248)A bax polymorphism was done by the polymerase chain reaction (PCR) and subsequent restriction analysis as described. 1 Genotype distribution between 112 CLL patients (87 GG, 21 AG, 4 AA) and 95 age-matched healthy controls (79 GG, 15 AG, 1 AA) were not significantly different suggesting that this polymorphism does not increase the susceptibility for B-CLL (G-allele frequency CLL patients: 0.87; controls: 0.91).
Time periods from first diagnosis to initiation of chemotherapy, a surrogate marker for disease progression, were not different in patients displaying the combined À248AG and AA (median progression-free survival 46 months) or the À248GG genotype (median progression-free survival 96 months; P ¼ 0.664 (Figure 1) ). Moreover, no genotype-dependent significant difference in progression-free survival was evident when analyzing stage A (P ¼ 0.33) and stage B/C (P ¼ 0.12) patients separately. Similar results were observed in a subgroup analysis of prognostically more favorable CD38 negative (P ¼ 0.34) and ZAP-70 negative (P ¼ 0.24) CLL patients. Moreover, genotypes were evenly distributed between different Binet stages as well as different cytogenetic risk groups (11qÀ, þ 12q, 13qÀ and 17pÀ).
In conclusion, our data do not support a substantial role of the regulatory G(À248)A bax polymorphism as a prognostic marker in B-CLL, at least not for progression-free survival. Genotype-dependent disease progression in patients with B-CLL. Progression-free survival of patients displaying the BAX -248AA or AG genotypes (N ¼ 25) versus BAX-248GG (N ¼ 87) genotypes. Statistical analysis was performed using the log-rank test.
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